{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T02:18:52Z","timestamp":1789006732767,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000874","name":"Brain & Behavior Research Foundation","doi-asserted-by":"publisher","award":["20785"],"award-info":[{"award-number":["20785"]}],"id":[{"id":"10.13039\/100000874","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000874","name":"Brain & Behavior Research Foundation","doi-asserted-by":"publisher","award":["540679"],"award-info":[{"award-number":["540679"]}],"id":[{"id":"10.13039\/100000874","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["K23MH100264"],"award-info":[{"award-number":["K23MH100264"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.schres.2018.07.019","type":"journal-article","created":{"date-parts":[[2018,7,17]],"date-time":"2018-07-17T14:51:03Z","timestamp":1531839063000},"page":"64-71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":108,"special_numbering":"C","title":["Cytokines in cerebrospinal fluid of patients with schizophrenia spectrum disorders: New data and an updated meta-analysis"],"prefix":"10.1016","volume":"202","author":[{"given":"Juan A.","family":"Gallego","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily A.","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6002-8046","authenticated-orcid":false,"given":"Sehba","family":"Husain-Krautter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Madeline Fagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Moreno-Merino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan A.","family":"del Ojo-Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas L.","family":"Rothstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Lencz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil K.","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.schres.2018.07.019_bb0005","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/1471-2377-9-S1-S3","article-title":"Characteristics of compounds that cross the blood-brain barrier","volume":"9","author":"Banks","year":"2009","journal-title":"BMC Neurol."},{"key":"10.1016\/j.schres.2018.07.019_bb0010","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000097202","article-title":"Passage of cytokines across the blood-brain barrier","volume":"2","author":"Banks","year":"1995","journal-title":"Neuroimmunomodulation"},{"key":"10.1016\/j.schres.2018.07.019_bb0015","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1515\/JBCPP.1995.6.1.61","article-title":"Changes in interleukin-1B and soluble interleukin-2 receptor levels in CSF and serum of schizophrenic patients","volume":"6","author":"Barak","year":"1995","journal-title":"J. Basic Clin. Physiol. Pharmacol."},{"key":"10.1016\/j.schres.2018.07.019_bb0020","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/schbul\/sbq146","article-title":"Maternal infection and schizophrenia: implications for prevention","volume":"37","author":"Brown","year":"2011","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2018.07.019_bb0025","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1001\/archpsyc.58.11.1032","article-title":"Maternal infections and subsequent psychosis among offspring","volume":"58","author":"Buka","year":"2001","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2018.07.019_bb0030","doi-asserted-by":"crossref","first-page":"e777","DOI":"10.1038\/tp.2016.40","article-title":"In vivo markers of inflammatory response in recent-onset schizophrenia: a combined study using [11C]DPA-713 PET and analysis of CSF and plasma","volume":"6","author":"Coughlin","year":"2016","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.schres.2018.07.019_bb0035","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.schres.2016.10.040","article-title":"Reduced superoxide dismutase-1 (SOD1) in cerebrospinal fluid of patients with early psychosis in association with clinical features","volume":"183","author":"Coughlin","year":"2017","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2018.07.019_bb0040","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.schres.2010.05.014","article-title":"Structural brain alterations in schizophrenia following fetal exposure to the inflammatory cytokine interleukin-8","volume":"121","author":"Ellman","year":"2010","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2018.07.019_bb0045","first-page":"383","article-title":"Interleukin 1-a and interleukin-2 in cerebrospinal fluid of schizophrenic subjects","volume":"13","author":"El-Mallakh","year":"1992","journal-title":"NeuroPsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2018.07.019_bb0050","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1038\/sj.npp.1300217","article-title":"Elevated interleukin-6 in the cerebrospinal fluid of a previously delineated schizophrenia subtype","volume":"28","author":"Garver","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"Suppl 2","key":"10.1016\/j.schres.2018.07.019_bb0055","doi-asserted-by":"crossref","first-page":"S217","DOI":"10.1007\/s10072-017-3034-2","article-title":"Cerebrospinal fluid analysis and the determination of oligoclonal bands","author":"Gastaldi","year":"2017","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.schres.2018.07.019_bb0060","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1038\/mp.2016.3","article-title":"A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression","volume":"21","author":"Goldsmith","year":"2016","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.schres.2018.07.019_bb0065","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1093\/schbul\/sbu052","article-title":"Inflammatory molecular signature with infectious agents in psychosis","volume":"40","author":"Hayes","year":"2014","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2018.07.019_bb0070","first-page":"387","article-title":"IL-6 enhances the nuclear translocation of DNA cytosine-5-methyltransferase 1 (DNMT1) via phosphorylation of the nuclear localization sequence by the AKT kinase","volume":"6","author":"Hodge","year":"2007","journal-title":"Cancer Genomics Proteomics"},{"key":"10.1016\/j.schres.2018.07.019_bb0075","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1742-2094-7-52","article-title":"Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance","volume":"7","author":"Jarius","year":"2010","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.schres.2018.07.019_bb0080","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000119130","article-title":"Plasma and interleukin-1B and interleukin-6 in hospitalized schizophrenia patients","volume":"30","author":"Katila","year":"1994","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.schres.2018.07.019_bb0085","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1124\/mol.108.051763","article-title":"The Reelin and GAD67 promoters are activated by epigenetic drugs that facilitate the disruption of local repressor complexes","volume":"75","author":"Kundakovic","year":"2009","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.schres.2018.07.019_bb0090","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1176\/ajp.150.9.1408","article-title":"Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenia patients","volume":"150","author":"Licinio","year":"1993","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2018.07.019_bb0095","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1034\/j.1600-0447.2003.00052.x","article-title":"Prenatal exposure to influenza as a risk factor for adult schizophrenia","volume":"107","author":"Limosin","year":"2003","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2018.07.019_bb0105","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","article-title":"Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects","volume":"70","author":"Miller","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2018.07.019_bb0110","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0920-9964(94)00045-A","article-title":"Immunoglobulin and albumin content of cerebrospinal fluid in schizophrenic patients: relationship to negative symptomatology","volume":"14","author":"Muller","year":"1995","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2018.07.019_bb0115","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0920-9964(97)00008-X","article-title":"CSF IL-l and IL-2 in medicated schizophrenic patients and normal volunteers","volume":"25","author":"Rapaport","year":"1997","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2018.07.019_bb0120","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0022-510X(00)00501-3","article-title":"Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs","volume":"184","author":"Reiber","year":"2001","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.schres.2018.07.019_bb0125","first-page":"421","article-title":"Biological insights from 108 schizophrenia-associated genetic loci","volume":"511","author":"Ripke","year":"2014","journal-title":"Nat. Genet."},{"key":"10.1016\/j.schres.2018.07.019_bb0130","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jpsychires.2012.12.001","article-title":"Increased cerebrospinal fluid interleukin-6 levels in patients with schizophrenia and those with major depressive disorder","volume":"47","author":"Sasayama","year":"2013","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.schres.2018.07.019_bb0135","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1503\/jpn.140126","article-title":"Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia \u2014 significance for activation of the kynurenine pathway","volume":"40","author":"Schwieler","year":"2015","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.schres.2018.07.019_bb0140","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nature16549","article-title":"Schizophrenia risk from complex variation of complement component 4","volume":"530","author":"Sekar","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.schres.2018.07.019_bb0145","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/biomet\/73.3.751","article-title":"An improved Bonferroni procedure for multiple tests of significance","volume":"73","author":"Simes","year":"1986","journal-title":"Biometrika"},{"key":"10.1016\/j.schres.2018.07.019_bb0150","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/mp.2009.52","article-title":"Activation of brain interleukin-1b in schizophrenia","volume":"14","author":"Soderlund","year":"2009","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.schres.2018.07.019_bb0155","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/schbul\/sbt139","article-title":"Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update","volume":"40","author":"Sommer","year":"2014","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2018.07.019_bb0160","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.schres.2013.10.011","article-title":"Antipsychotics' effects on blood levels of cytokines in schizophrenia: a metaanalysis","volume":"151","author":"Tourjman","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2018.07.019_bb0165","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.schres.2014.03.005","article-title":"Cytokine function in medication-naive first episode psychosis: a systematic review and meta-analysis","volume":"155","author":"Upthegrove","year":"2014","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2018.07.019_bb0170","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0165-1781(99)00053-0","article-title":"Elevated interleukin-6 in schizophrenia","volume":"87","author":"Van Kammen","year":"1999","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2018.07.019_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbi.2016.03.010","article-title":"The blood-brain barrier in systemic inflammation","volume":"60","author":"Varatharaj","year":"2017","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.schres.2018.07.019_bb0180","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s00406-011-0280-9","article-title":"Cerebrospinal fluid biomarker candidates of schizophrenia: where do we stand?","volume":"262","author":"Vasic","year":"2012","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.schres.2018.07.019_bb0185","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1006\/exnr.1996.0200","article-title":"TGFb1 and TGFb2 concentrations are elevated in Parkinson's disease in ventricular cerebrospinal fluid","volume":"142","author":"Vawter","year":"1996","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.schres.2018.07.019_bb0190","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0893-133X(96)00143-1","article-title":"Transforming growth factors beta 1 and beta 2 in the cerebrospinal fluid of chronic schizophrenic patients","volume":"16","author":"Vawter","year":"1997","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2018.07.019_bb0195","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/schbul\/sbx035","article-title":"Meta-analysis of cerebrospinal fluid cytokine and tryptophan catabolite alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder, and depression","volume":"44","author":"Wang","year":"2018","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2018.07.019_bb0200","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/jnc.12263","article-title":"IL-1\u03b2 and TNF-\u03b1 induce neurotoxicity through glutamate production: a potential role for neuronal glutaminase","volume":"125","author":"Ye","year":"2013","journal-title":"J. Neurochem."},{"key":"10.1016\/j.schres.2018.07.019_bb0205","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00213-008-1295-4","article-title":"Lower serum cytokine levels in smokers than nonsmokers with chronic schizophrenia on long-term treatment with antipsychotics","volume":"201","author":"Zhang","year":"2008","journal-title":"Psychopharmacology"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996418304365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996418304365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T19:31:55Z","timestamp":1661628715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996418304365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":40,"alternative-id":["S0920996418304365"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2018.07.019","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytokines in cerebrospinal fluid of patients with schizophrenia spectrum disorders: New data and an updated meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2018.07.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}